PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy

Journal of Hematology & Oncology

Wenxin Zheng⁶  Beihua Kong⁶  Janiel M Cragun¹  Tingguo Zhang³  Bingbing Yuan⁵  Zeng Yuan²  Jie Li²  Yiying Wang⁴  Yue Wang⁴ 

[1] Department of Obstetrics and Gynecology, College of Medicine, University of Arizona, 1501 N. Campbell Avenue, #5205, Tucson, AZ 85724, USA;Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Ji’nan, Shandong 250012, China;Department of Pathology, Qilu Hospital, Shandong University, Ji’nan, Shandong 250012, China;Department of Pathology, University of Arizona College of Medicine, Tucson, AZ 85724, USA;Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA;Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA

关键词: Marker;    Origin;    Neoadjuvant chemotherapy;    Ovarian cancer;    Ascitic fluid;    PAX8;   

Others  :  817468
DOI  :  10.1186/1756-8722-6-60

 received in 2013-07-18, accepted in 2013-08-15,  发布年份 2013

【 摘 要 】

Background

Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy.

Methods

Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50).

Results

Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia.

Conclusions

PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Schwartz PE, Zheng W: Neoadjuvant chemotherapy for advanced ovarian cancer: the role of cytology in pretreatment diagnosis. Gynecol Oncol 2003, 90:644-650.
• [2]Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953.
• [3]McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005, 22:3-32.
• [4]Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000, 13:962-972.
• [5]Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, et al.: A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011, 35:816-826.
• [6]Nonaka D, Chiriboga L, Soslow RA: Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008, 32:1566-1571.
• [7]Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, Hirsch MS: PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010, 34:627-635.
• [8]Sneige N, Fanning CV: Peritoneal washing cytology in women: diagnostic pitfalls and clues for correct diagnosis. Diagn Cytopathol 1992, 8:632-642. discussion 640–632
• [9]DeMay RM: Cytopathology of false negatives preceding cervical carcinoma. Am J Obstet Gynecol 1996, 175:1110-1113.
• [10]Sneige N, Fernandez T, Copeland LJ, Katz RL: Mullerian inclusions in peritoneal washings. Potential source of error in cytologic diagnosis. Acta Cytol 1986, 30:271-276.
• [11]Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W: Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol 2011, 24:1488-1499.
• [12]Knoepp SM, Kunju LP, Roh MH: Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology. Diagn Cytopathol 2012, 40:667-672.
• [13]Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT: Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006, 130:823-827.
• [14]Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, O'Toole KM: Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol 2009, 22:1218-1227.
• [15]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [16]McKnight R, Cohen C, Siddiqui MT: Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma. Cancer Cytopathol 2010, 118:298-302.
• [17]Cannistra SA: Cancer of the ovary. N Engl J Med 1993, 329:1550-1559.
• [18]Deo SV, Goyal H, Shukla NK, Raina V, Kumar L, Srinivas G: Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006, 43:117-121.
• [19]Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
• [20]Kurman RJ, Shih Ie M: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011, 42:918-931.
• [21]Tacha D, Zhou D, Cheng L: Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol 2011, 19:293-299.
• [22]Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, McDonald JF: Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007, 104:331-337.
• [23]Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al.: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008, 5:e232.
• [24]Nonaka D, Chiriboga L, Soslow RA: Expression of Pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. American J Surg Pathol 2008, 32:1566-1571.
• [25]Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, Pejovic T, Lele S: Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecol Oncol 2012, 127:198-201.
• [26]Tong GX, Devaraj K, Hamele-Bena D, Yu WM, Turk A, Chen X, Wright JD, Greenebaum E: Pax8: a marker for carcinoma of Mullerian origin in serous effusions. Diagn Cytopathol 2011, 39:567-574.